C-OP04PharmatrophiX
small molecules, p75 modulation, neurotrophin receptors
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-OP04
C-OP04C-OP04small molecules, p75 modulation, neurotrophin receptors
0-100 chain-logic scale · 15 dimensions · scored on public evidence
PharmatrophiX small molecules, p75 modulation, neurotrophin receptors
PharmatrophiX is a clinical-stage biopharmaceutical company focused on disease-modifying therapies for neurodegenerative diseases. Its pipeline includes small-molecule drugs targeting p75 as well as TrkB and TrkC receptors. Its lead asset, LM11A-31, is described as a first-in-class small molecule targeting the p75 neurotrophin receptor and has completed a Phase 2a clinical trial.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
PharmatrophiX — Translational · Bottom quartile. Derived deterministically from 1 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic